Should you buy Vertex Pharmaceuticals Incorporated stock now?
Yes, the technical signal for Vertex Pharmaceuticals Incorporated is currently BUY. Vertex Pharmaceuticals Incorporated trades at $483.29 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.792 with falling momentum (signal: 2.044); RSI is at 53.4 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $558.32 points to 15.5% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Vertex Pharmaceuticals Incorporated stock?
The average analyst price target for Vertex Pharmaceuticals Incorporated is $558.32. The current price is $483.29, which gives an upside of 15.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $502.49 and $614.15.
Is Vertex Pharmaceuticals Incorporated a dividend stock?
No, Vertex Pharmaceuticals Incorporated does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Vertex Pharmaceuticals Incorporated stock?
Vertex Pharmaceuticals Incorporated is rated as a stock with moderately low risk. the annual standard deviation is 27.9%, which classifies the stock as moderately low risk.
Is Vertex Pharmaceuticals Incorporated overvalued?
No, Vertex Pharmaceuticals Incorporated is considered undervalued based on the analyst price target (15.5% upside). Vertex Pharmaceuticals Incorporated has the following valuation ratios: a P/E ratio of 27.9 (moderately to highly valued), a P/S ratio of 9.6, a P/B ratio of 6.3. The analyst price target suggests that the stock is undervalued by 15.5%.
Is Vertex Pharmaceuticals Incorporated overbought?
No, Vertex Pharmaceuticals Incorporated is not overbought. RSI is at 53.4 (neutral zone). The technical indicators show: RSI is at 53.4 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.5% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Vertex Pharmaceuticals Incorporated earnings report?
The date of the next earnings report for Vertex Pharmaceuticals Incorporated has not been published yet. Check the company's investor calendar for updates.
Is Vertex Pharmaceuticals Incorporated shorted?
Yes, Vertex Pharmaceuticals Incorporated is shorted with 2.2% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Vertex Pharmaceuticals Incorporated stock?
No, insiders are not buying Vertex Pharmaceuticals Incorporated shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 12 sales. On a net basis, 10,401,722 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 16,491,047 $ sold. Active sellers include Tatsis Ourania, McKechnie Duncan, Liu Joy and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Vertex Pharmaceuticals Incorporated a good stock?
Based on our total score, Vertex Pharmaceuticals Incorporated is rated as a good stock with a total score of 64 out of 100. The stock scores above average on value, quality and momentum – it is among the top 36% in our database. The score is made up of Value: 34/100, Quality: 86/100, Momentum: 71/100. In addition: analysts see 15.5% upside to the price target; technical signal: Strong Buy. Whether Vertex Pharmaceuticals Incorporated is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Vertex Pharmaceuticals Incorporated stock?
The outlook for Vertex Pharmaceuticals Incorporated based on current data: the average analyst price target is $558.32 (+15.5%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 27.9 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Vertex Pharmaceuticals Incorporated stock moving?
Vertex Pharmaceuticals Incorporated is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Vertex Pharmaceuticals Incorporated go?
The average analyst price target for Vertex Pharmaceuticals Incorporated is $558.32, which corresponds to a potential gain of 15.5% from the current price of $483.29. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Vertex Pharmaceuticals Incorporated fall?
We lack enough history to give a specific floor for Vertex Pharmaceuticals Incorporated. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals, eller bare vrtx.us, er et biotekfirma, der primært tjener penge på at udvikle og sælge behandlinger mod cystisk fibrose (CF). De er især kendt for deres CF-medicin som TRIKAFTA/KAFTRIO, der kan bruges af patienter helt ned til to år.
Derudover sælger V... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Vertex Pharmaceuticals Incorporated as an investment.
Did Vertex Pharmaceuticals Incorporated raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Vertex Pharmaceuticals Incorporated. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Vertex Pharmaceuticals Incorporated making money or losing money?
Yes, Vertex Pharmaceuticals Incorporated is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 35.0% — which is excellent. The operating margin (profit before interest and taxes) is 38.1%. At a P/E ratio of 27.9, you currently pay 27.9 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Vertex Pharmaceuticals Incorporated go bankrupt?
The bankruptcy risk of Vertex Pharmaceuticals Incorporated is rated as low. Altman Z2 (a model for assessing financial distress) is 8.18 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 37% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Vertex Pharmaceuticals Incorporated have a lot of debt?
No, Vertex Pharmaceuticals Incorporated has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 37%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
